QurCan Therapeutics has developed the next-generation nanoparticle C-TERP (CNS-Target-Engineered Responsive Polymer) platform for nonviral, repeat-dosable, and targeted delivery of genetic medicine (oligos, mRNA, and DNA) across the Blood Brain Barrier.  Recent experiments confirm in widespread parenchymal distribution across key brain regions, as well as systemic delivery of TERP-mRNA to the CNS in marmosets and efficacy of TERP-ASO in the Dravet Syndrome mouse model. These findings establish C-TERP as a promising and safe non-viral delivery system for systemic CNS-targeted gene therapy, with strong translational potential for advancing a new generation of genetic medicines targeting neurodegenerative and rare CNS disorders